Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties.

Patient Preference and Adherence
William MontgomeryGavan Harrison

Abstract

Orally disintegrating olanzapine (ODO) is a rapid-dissolving formulation of olanzapine which disintegrates in saliva almost immediately, developed as a convenient and adherence-enhancing alternative to the standard olanzapine-coated tablet (SOT). Clinical studies, which form the basis of this review, have shown ODO and SOT to have similar efficacy and tolerability profiles. However, ODO appears to have a number of advantages over SOT in terms of adherence, patient preference, and reduction in nursing burden. Overall, the existing clinical data suggests that compared to SOT, ODO is not only well-suited for difficult-to-treat, agitated, and/or nonadherent patients but, due to its potential ability to improve adherence and greater patient preference, may also be an appropriate formulation for the majority of patients for which olanzapine is the antipsychotic of choice.

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1995·Schizophrenia Bulletin·P J Weiden, M Olfson
Jun 30, 1994·The New England Journal of Medicine·J P Kassirer
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS Hamilton
Jun 13, 1998·The Journal of Pharmacy and Pharmacology·H Seager
May 29, 2001·Psychiatric Services : a Journal of the American Psychiatric Association·B L SvarstadJ K Sweeney
Jan 14, 2003·The Journal of Clinical Psychiatry·Diana O Perkins
Mar 29, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Patricia ThiedaJohn Kane
Aug 2, 2003·The International Journal of Neuropsychopharmacology·Bruce J KinonSara Kollack-Walker
Aug 5, 2004·Psychiatric Services : a Journal of the American Psychiatric Association·Peter J WeidenJulie Locklear
Mar 1, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joseph M Pierre
May 17, 2005·Patient Education and Counseling·Kristina H JahngM Robin DiMatteo
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 4, 2005·The American Journal of Psychiatry·Alan BreierJohn M Kane
Jun 7, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Emmanuel StipPierre Landry
Dec 2, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Josep Maria HaroUNKNOWN SOHO Study Group
Jun 27, 2007·The Journal of Clinical Psychiatry·Dan CooperJean-Pierre Grégoire
Sep 1, 2007·European Psychiatry : the Journal of the Association of European Psychiatrists·Marc-Antoine CrocqDominique Provost
Sep 12, 2007·Current Medical Research and Opinion·Jamie KaragianisLeslie Citrome
Mar 4, 2008·The Journal of Clinical Psychiatry·Michael R LawAlyce S Adams
Mar 14, 2008·Human Psychopharmacology·Jamie KaragianisBharat Chawla
Sep 20, 2008·CNS Neuroscience & Therapeutics·Luis SanInmaculada Gilaberte
Aug 27, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Hikaru HoriJun Nakamura
Jan 12, 2010·BMC Psychiatry·Haya Ascher-SvanumRobert R Conley

❮ Previous
Next ❯

Citations

Oct 24, 2013·Drugs·Kimberly Nordstrom, Michael H Allen
Aug 31, 2013·AAPS PharmSciTech·Melanie KöllmerRichard A Gemeinhart
Aug 22, 2014·AAPS PharmSciTech·Sarah BaltzleyAbeer M Al-Ghananeem
Nov 18, 2014·Expert Opinion on Drug Safety·Richard MusilMichael Hamerle
May 3, 2014·Drug Development and Industrial Pharmacy·Zhenzhong GeChunsheng Gao
Jun 27, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Ziyaur RahmanMansoor A Khan
Jun 9, 2016·Journal of Palliative Medicine·Maria FeltonJennifer Pruskowski
Aug 19, 2016·Drug Development and Industrial Pharmacy·Helal Abdo MoqbelMohamed Ahmed El-Nabarawi
Jan 18, 2020·Pharmaceutics·Enrica MendittoIsabel F Almeida

❮ Previous
Next ❯

Software Mentioned

PLATYPUS

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here